Study on the Correlation Between Gene Mutation and TCM Syndrome Types in Metastatic Colorectal Cancer

Not Applicable

• Conditions: Traditional Chinese Medicine; Gene Mutation-Related Cancer
• Interventions: Drug: Traditional Chinese Medicine

• Registration Number: NCT04661046
• Lead Sponsor: Shanghai University of Traditional Chinese Medicine

Brief Summary

To explore the correlation between gene mutations of metastatic colorectal cancer and TCM syndrome types based on Second-generation sequencing technology.

Detailed Description

Not available

Study Timeline

• Status Verified: 2020-11
• Study First Submitted: 2020-11-20
• Study Start: 2020-11-30
• Study First Submitted QC: 2020-12-08
• Last Update Submitted: 2020-12-08
• Study First Posted: 2020-12-09
• Last Update Posted: 2020-12-09
• Primary Completion: 2022-08-31
• Study Completion: 2022-08-31

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

1. A clear pathological diagnosis is a patient with colorectal cancer;
2. Have complete TNM staging information;
3. There is a clear diagnosis of the location and time of metastasis;
4. Age ≥18 years old, ≤80 years old, male or female;
5. There is a clear time for the first treatment with Chinese medicine;
6. Patients who can receive long-term follow-up. -

Exclusion Criteria

1. Patients with colorectal cancer diagnosed pathologically as adenosquamous carcinoma, squamous cell carcinoma, carcinoid, small cell carcinoma, malignant lymphoma, etc.;
2. Patients with double cancer, multiple or metastatic colorectal cancer;
3. Combined with severe acute and chronic diseases that may affect treatment and prognosis, such as myocardial infarction, stroke, severe renal insufficiency and mental illness;-

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
TCM Syndrome Types	Traditional Chinese Medicine	Traditional Chinese Medicine

Primary Outcome Measures

Name	Time	Method
Overall Survival	2 years	OS
Progression Free Survival	2 years	PFS